Literature DB >> 19902154

[Prevention of stroke: what is evidence based?].

S Lüders1, J Schrader.   

Abstract

On the background of aging population an increase of patients suffering from stroke has to be expected during the next years and decades. Strokes are the 3rd leading cause of death and reason for disability in Germany and many other countries. An effective treatment of the modifiable risk factors hypertension, hyperlipidemia, diabetes mellitus, atrial fibrillation, smoking, alcohol consumption, and adipositas is of enormous impact. Due to the linear relationship between blood pressure and risk of stroke, the treatment of hypertension is the most important and effective one in primary as well as in secondary prevention. Treatment with platelet inhibitors plays an additional important role in secondary prevention. Patients with atrial fibrillation should receive an effective oral anticoagulatory therapy when there are certain risk factors.

Entities:  

Mesh:

Year:  2009        PMID: 19902154     DOI: 10.1007/s00108-009-2465-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  37 in total

1.  Cardiovascular protection and blood pressure reduction: a meta-analysis.

Authors:  J A Staessen; J G Wang; L Thijs
Journal:  Lancet       Date:  2001-10-20       Impact factor: 79.321

Review 2.  The global stroke initiative.

Authors:  Ruth Bonita; Shanthi Mendis; Thomas Truelsen; Julien Bogousslavsky; James Toole; Frank Yatsu
Journal:  Lancet Neurol       Date:  2004-07       Impact factor: 44.182

3.  Discontinuation of statin treatment in stroke patients.

Authors:  Matthias Endres; Ulrich Laufs
Journal:  Stroke       Date:  2006-08-31       Impact factor: 7.914

4.  Survival and recurrent strokes in patients with different subtypes of stroke: a fourteen-year follow-up study.

Authors:  S E Eriksson; J E Olsson
Journal:  Cerebrovasc Dis       Date:  2001       Impact factor: 2.762

5.  Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.

Authors:  Paul T Akins; Harvey A Feldman; Robert G Zoble; David Newman; Stefan G Spitzer; Hans-Christoph Diener; Gregory W Albers
Journal:  Stroke       Date:  2007-01-25       Impact factor: 7.914

6.  15-year longitudinal study of blood pressure and dementia.

Authors:  I Skoog; B Lernfelt; S Landahl; B Palmertz; L A Andreasson; L Nilsson; G Persson; A Odén; A Svanborg
Journal:  Lancet       Date:  1996-04-27       Impact factor: 79.321

7.  Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

Review 8.  Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis.

Authors:  Matthew F Giles; Peter M Rothwell
Journal:  Lancet Neurol       Date:  2007-11-13       Impact factor: 44.182

9.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

Authors:  James F Toole; M René Malinow; Lloyd E Chambless; J David Spence; L Creed Pettigrew; Virginia J Howard; Elizabeth G Sides; Chin-Hua Wang; Meir Stampfer
Journal:  JAMA       Date:  2004-02-04       Impact factor: 56.272

10.  Telmisartan to prevent recurrent stroke and cardiovascular events.

Authors:  Salim Yusuf; Hans-Christoph Diener; Ralph L Sacco; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  N Engl J Med       Date:  2008-08-27       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.